SDGR News
Closing Power Hour: Biotech, AI, Energy and Crypto Stories Take Center Stage
The final stretch of trading is bringing a fresh batch of catalysts across biotech, energy, AI and digital assets, with the following names delivering developments capable of reshaping their narratives. Aethlon Medical (NASDAQ:AEMD), NeOnc Technologies Holdings (NASDAQ:NTHI), bioAffinity Technologies (NASDAQ:BIAF), Turbo Energy (NASDAQ:TURB), CID HoldCo (NASDAQ:DAIC), Paradium.AI (NYSE:PAAI), StablecoinX (NASDAQ:USDE), FuelCell Energy (NASDAQ:FCEL), and Schrödinger (NASDAQ:SDGR).
24-7 Market News
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Schrdinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the companys common stock to three newly hired employees. These grants were made pursuant to the companys 2021 Inducement Equity Incentive...
Business Wire
SDGR Crosses Above Average Analyst Target
In recent trading, shares of Schrodinger Inc (Symbol: SDGR) have crossed above the average analyst 12-month target price of $21.43, changing hands for $23.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valu...
Nasdaq News: Markets
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
Schrodinger (SDGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033PR NewswireAUSTIN, Texas, Sept. 14, 2026 AUSTIN, Texas, Sept. 14, 2026 /PRNewswire/ -- USA News Group News Commentary- Artificial intelligence is moving from the edges...
PR Newswire
Schrdinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs
Schrdinger, Inc. (Nasdaq: SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on developing innovative therapies for immunology and inflammation. Tectora concurrently closed a $55 million...
Business Wire
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?
Recursion Pharmaceuticals is expanding its clinical pipeline across oncology and rare diseases, with REC-4881 and multiple programs offering potential growth catalysts.
Zacks
"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty
"Schrodinger's Strait:" Why Hormuz Now Exists in a State of Permanent Uncertainty...
Yahoo! Finance: News
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030 PR Newswire AUSTIN, Texas, Sept. 3, 2026 AUSTIN, Texas, Sept. 3, 2026 /PRNewswire/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt...
PR Newswire
Schrdinger to Present at Morgan Stanley Global Healthcare Conference
Schrdinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the Investors...
Business Wire